{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["31(3)"],"submitter":["Kim DDH"],"pubmed_abstract":["This is a consensus-based Canadian guideline whose primary purpose is to standardize and facilitate the management of chronic graft-versus-host disease (cGvHD) across the country. Creating uniform healthcare guidance in Canada is a challenge for a number of reasons including the differences in healthcare authority structure, funding and access to healthcare resources between provinces and territories, as well as the geographic size. These differences can lead to variable and unequal access to effective therapies for GvHD. This document will provide comprehensive and practical guidance that can be applied across Canada by healthcare professionals caring for patients with cGvHD. Hopefully, this guideline, based on input from GvHD treaters across the country, will aid in standardizing cGvHD c"],"journal":["Current oncology (Toronto, Ont.)"],"pagination":["1426-1444"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10968999"],"repository":["biostudies-literature"],"pubmed_title":["Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development."],"pmcid":["PMC10968999"],"pubmed_authors":["Novitzky-Basso I","Popradi G","CTTC Chronic GVHD Guideline Working Group","Lachance S","White J","Nampoothiri RV","Schultz KR","Kumar R","Jamani K","Fraga C","Lepic K","Allan D","Paulson K","Elemary M","Deotare U","Lemieux C","Kim DDH","Law AD","Walker I"],"additional_accession":[]},"is_claimable":false,"name":"Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development.","description":"This is a consensus-based Canadian guideline whose primary purpose is to standardize and facilitate the management of chronic graft-versus-host disease (cGvHD) across the country. Creating uniform healthcare guidance in Canada is a challenge for a number of reasons including the differences in healthcare authority structure, funding and access to healthcare resources between provinces and territories, as well as the geographic size. These differences can lead to variable and unequal access to effective therapies for GvHD. This document will provide comprehensive and practical guidance that can be applied across Canada by healthcare professionals caring for patients with cGvHD. Hopefully, this guideline, based on input from GvHD treaters across the country, will aid in standardizing cGvHD c","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-25T21:40:04.962Z","creation":"2024-11-06T00:52:19.23Z"},"accession":"S-EPMC10968999","cross_references":{"pubmed":["38534941"],"doi":["10.3390/curroncol31030108"]}}